Adicet Bio to delay phase 1 lupus update until Q3 2026
Adicet Bio delayed the release of Phase 1 results for prula-cel in lupus due to added patient follow-up. The progress in pivotal trial design suggests a smoother regulatory path forward, supporting the stock's medium-term outlook.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day